Recherche Translationnelle en Oncogénèse Génito-Urinaire

Contacts


The INSERM U955 Equipe/team 07 is a strong association of clinicians, oncologists, pathologists, biochemists and basic researchers in a dedicated environment that allows high scientific level facilities working on prostate and bladder cancers.

 

The goal is to determine the most relevant molecular events to define the molecular risk factors associated with therapy success and resistance and to identify new therapeutic targets.

 

During the past 5 years, the group worked on identifying biomarkers to try to reduce overdiagnosis and personalized therapeutic approaches in prostate cancer such as urine PCA3, serum testosterone, betaTUBIII, protocadherin PC, androgen receptor and telomerase instability and molecular pathways PI3K/Akt, Wnt (Wnt / β-catenin).

An inhibitor of nucleophosmin N6L was also evaluated. Hormonal environment was also evaluated in Caucasian and Caribbean patients and highlighted that estrone and estrone sulfate levels were correlated with aggression.

The team identified FSH receptor on the surface of endothelial cells that correlates with tumor behavior. In bladder cancer, FGFR3 mutations correlated with superficial cancers was validated and loss of CDKN2A expression was found to be associated with aggressiveness.

Two programs for Excellence in bladder cancer were initiated: (1) CIT on the association between cancer and the presence of aggressive T2 MRES (Regional Multiple Epigenetic Silencing) phenotype and on the characterization of a subset of T2 with an addiction to EGFR pathway and (2) the FP7 program involving DECaNBio with Spain in 1070 patients with bladder cancer to explore by SRM the aggressiveness and recurrence of low-grade cancer markers.


The next projects on prostate cancer are to continue to investigate biomarkers of lethal prostate cancer using high-throughput microarray technologies (PAIR Prostate), to validate new prostate cancer treatments such as mdv3100, orteronel or abiraterone, to find molecular pathways involved in resistance on preclinical models, to study regulations of cancer cell proliferation and invasion by Heparin-affin regulatory growth factor (HARP) and to determine hormonal profiles of prostate cancer patients.

For bladder cancer, our group will develop the molecular taxonomy of bladder cancer and continue to validate new prognostic factors.


Voir aussi : Service d’Urologie, Hôpital Henri Mondor


Publications récentes

Giton F, Sirab N, Franck G, Gervais M, Schmidlin F, Ali T, Allory Y, Taille A, Vacherot F, Loric S, Fiet J. Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate.

J Steroid Biochem Mol Biol. 2015 May 6;152:89-100.

Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de la Taille A, Allory Y. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.

Cancer. 2015 May 1;121(9):1422-30.

Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N. Inflammatory biomarkers and bladder cancer prognosis: a systematic review.

Eur Urol. 2014 Dec;66(6):1078-91.

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F. CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.

Oncotarget. 2014 Dec 26. [Epub ahead of print]

Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Pérez C, López-Bigas N, Kamoun A, Neuzillet Y, Gestraud P, Grieco L, Rebouissou S, de Reyniès A, Benhamou S, Lebret T, Southgate J, Barillot E, Allory Y, Zinovyev A, Radvanyi F. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.

Cell Rep. 2014 Nov 20;9(4):1235-45.

Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y, de la Taille A, Vacherot F. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.

Neoplasia. 2013 Jul;15(7):761-72.

Sirab N, Terry S, Giton F, Caradec J, Chimingqi M, Moutereau S, Vacherot F, de la Taille, Kouyoumdjian JC, Loric S. Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells.

Int J Cancer. 2012 Sep 15;131(6):1297-306.

Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Cancer Res. 2010 Nov 15;70(22):9253-64.

Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N. Expression of follicule-stimulating hormone receptor in tumor blood vessels.

N Engl J Med. 2010 Oct 21;363(17):1621-30.